#5

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

collection of information unless it displays	a valid OMB control number	_ 5
Application Number	09/922874	
Filing Date	August 6, 2001	
First Named Inventor	Elfida R. Grant, et.a	al.
Group Art Unit	1624 8	
Examiner Name	T. TRUOTER	-8
Attorney Docket Number	ORT-1482	

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite	U.S. Patent Docum	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-docyyyy	Clan Subclas Pages, columns, Liges, where celevant pagsages or relevant figures appear		
MI	1	US 5,506,231		Lipton	04-09-1996	514/289		
W1 V	2	US 5,519,035		Maise	05-21-1996	514/309		
		-						
	-							

## **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Cite Examiner mm-dd-yyyy T<sup>6</sup> Applicant of Cited Document figures appear KindCode<sup>5</sup> Office<sup>3</sup> Number<sup>4</sup> No.1 3 WO 99/00117 Manthappa WO 99/58982 Liu WO 99/34792 Alessandrini

Examiner	7/0	Date	12-2 03
Signature	-0000	Considered	0-2-00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

collection of information unless it displays	a vatid OMB control number.	
Application Number	09/922874	Z
Filing Date	August 6, 2001	<del></del>
First Named Inventor	Elfida R. Grant, et.	aD
Group Art Unit	1624	5
Examiner Name	T. TRUONES	8
Attorney Docket Number	ORT-1482	/29(

DEMARK	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	1
Examiner's	Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.¹ publisher, city and/or country where published	
tW1	6 / Ahn, N., et. al. (1991) J. Biol. Chem. 266:4220-4227 4 72	T
1	7 / Allessandrini, Al., et. al., (1999) Proc Natl Acad Sci USA 96:12866-9	
	8 / Anderson, N., et. al. (1990) Nature 343:651-653 👉	
	9 / Bading, H., Greenberg, M.E. (1991) Science 253:912-914 🗽	I -
	10 / Callaway, J., et. al. (1999) Stroke 12:2704-2712 2	1
	11 / Canzoniero, L., et al. J. (1996) J. Neurosci. Res. 45:226-236 🛪	
	12 V/Cheng, Y., et. al. (1998) J. Clin. Invest. 101:1992-1999	
	13 / Chijiwa, T., et. al. (1990) J. Biol. Chem. 265:5267-5272 🔀	
	14 / Courtney, M., et. al. (1990) J. Neurosci. 10:3873-3879 /	
	15 / Crews, C., Allessandrini, A., Erikson, R. (1992) Science 258:478-480	<u> </u>
	16 / Desdouits-Magnen, J., et. al. (1998) J. Neurochem. 70:524-530 /	
	17 // Enslen, H., et al. (1996) Proc Natl Acad Sci USA 93:10803-10808 /	
	18 / Favata, M.F., et al., (1998) J. Biol. Chem. 273:18623-18632 -	
	19 . Fiore, R.S., et al. (1993) J Neurochem 61:1626-1633 .	
	20 Grobin, A.C., (1999) Brain Research 827:1-11	
	21 / Heath, D., Vink, R. (1999) J. Neurosurg. 90:504-509 /	
	22 Menry, J., et al. (1998) J. Med. Chem. 41:4196-4198:	,
	23 🗸 Hu, B., Wieloch, T. (1994) J. Neurochem 62:1357-1367: 🛩	
	24 / Inhorn, R., Majerus, P. (1987) J. Biol. Chem. 262:15946-15952 /	
	25 //shii, T., et al. (1993) J. Biol. Chem. 268:2836-2843 /	
	26  √ Jaiswal, R., et al. (1994) Mol. Cell. Biol. 14:6944-6953 · ✓	<u> </u>
	27 //Jones-Vellenueve, et al. (1982) J. Cell. Biol. 94:253-262 //	ļ
	28 , / Jones-Vellenueve, et al. (1983) Mol. Cell Biol. 4:2271-2279 • /	<u> </u>
	29 / Jovanoic, J., et.al. (1996) Proc. Natl. Acad. Sci. USA 93:3679-3683 🚜	<u> </u>
	30 / Kindy, M. (1993) J Chereb Blood Flow Metab 13:372-377, /	ļ
	31 //Kobayashi, E., et al. (1989) Biochem. Biophys. Res. Commun. 159:548-553 //	<u> </u>
,	32 V Kurino, M., et al. (1995) J Neurochem 65:1282-1289 🗷	
	33 / Lander, H., et al. (1996) J. Biol. Chem. 271:19705-19709 -	
	34 ./ Laurie, D., et al. (1995) Brain Res. Mol. Brain Res. 32:94-108 /	<u> </u>
	35 🗸 Lee, J., et al. (1994) Nature 372:739-746 🗸	
	36 🗸 Lev, S., et al. (1995) Nature 376:737-745 🗸	
	37 Li, B., et al. (1999a) Eur. J. Biochem. 262:211-217 🗸	ļ
	38 √ [Ji, M., et al. (1999b) Brain Res. 1999:44-52: ✓	L
	39 ; McBurney, M.W., et al. (1982) Dev. Biol. 89:503-508 /	<b></b>
	40 ✓ Meldrum, B., Garthwaite, J. (1990) Trends Pharmacol Sci 11:379-387 ✓	<b>_</b>
	41 / Monyer, H., et. al. (1994) Neuron 12:529-540 /	<b></b>
	42 Monyer, H., et. al. (1992) Science 256:1217-1221.	<b></b>
	43 V/Moodie, S., et al. (1993) Science 260:1658-1661	<u> </u>
DVI	44 Morley, p., et al. (1995) J. Neurochem. 65:1093-1099 p	

Examiner Date Date	
LAZIMINE   Date   1 0 - 1) 2	
Signature Considered (a 2 2 3)	
Signature Considered Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

RECEIVEL

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a vaid OMB control numb

SUBSTITUTE FOR THE 1449 APTO

STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 3 of 3

a collection of information unless it displays a	s vatid OMB control number.	Z
Application Number	09/922658	-
Filing Date	August 6, 2001	0
First Named Inventor	Elfida R. Grant, etal.	7
Group Art Unit	1624	U
Examiner Name	T. TRUONUS	7
Attorney Docket Number	ORT-1483	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T
nitials*	No.1 publisher, city and/or country where published	
DVI	45 / Murray, B., et al. (1998) Proc. Natl. Acad. Sci. USA 95:11975-11980 🗷	
4	46 🗸 Onoda, T., et al. (1989) J. Nat. Prod. 52:1252-1257 🌶	
	47 , / Papin, C., et al. (1995) Oncogene 10:1647-1651	
	48 / Park, C., et. al. (1988) Ann. Neurol. 24:543-551 /	
	49 🗸 Pazos, a., et al. (1999) Brain Res. 846:186-195 🖊	
	50 V Pleasure,S., Lee, V. –Y. (1993) Journal of Neurosci. Res. 35:585-602	
	51 V Pleasure, S., et. al. (1992) J. Neurosci. 12:1802-1815	
	52 Nay, W.J., Gottlieb, D. I. (1993) Biochem. Biophys. Res. Comm. 197:1475-1482 /	
	53 V Rootwelt, T., et. al. (1998) J. Neurochem. 71:1544-1553 -	_
	54 / Rosen, L., et al. (1994) Neuron 12:1207-1221 /	
	55 🗸 Sakagami, H., Kondo, H. (1993) Brain Res Mol Brain Res 19:215-218 🖊	
	56 / Sakakibara, Y., et al. (2000) Neurosci Lett 281:111-114 /	
	57 / Sattler, R., et al. (1999) Science 284:1845-1848 🛩	
	58 / Schneggenburger, R., et al. (1993) Neuron 11:133-143 /	
	59 Schwartz-Bloom, R., et al. (1998) J Chereb Blood Flow Metab 18:548-558	
	60 🗸 Sola, C., et al. (1999) J. Neurosci. Res. 57:651-652 🖊	
	61 V Stanciu, M., et al. (2000) J. Biol. Chem. 275:12200-12206	<u> </u>
	62 🗸 Standaert, D., et al. (1994) J. Comp. Neurol. 343:1-16 🖍	
	63 / Takahashi, M., et al. (1998) J. Pharmacol. Exp. Ther. 287:559-566 🚜	
	64 //Tatlisumak, T., et al. (1998) Stroke 29:1952-1958 /	
	65 / Tokumitsu, H., et al. (1990) J. Biol. Chem. 265:4315-4320	
	66 //Turetsky, D.M., et al. (1993) J. Neurobiol. 24:1157-1169 /	
	67 \( \frac{1}{\taurski}, L., et al. (1998) Proc. Natl. Acad. Sci. USA 95:10960-10965 \( \tau \)	
	68 / Tymianski, M., et al. (1993) J. Neurosci. 13:2085-2104 /	
	69 / Nanhoutte, P., et al. (1999) Mol. Cell.Biol 19:136-146 /	
	70 Wasterlain, C., et al. (1996) Stroke 27:1236-1240 1	
	71 Xia, Z., et al. (1995) Science 270:1326-1331 -	
	72 Xia, Z., et al. (1998) J.Neurosci. 16:5425-5436 🗸	
	73 // Yang, D. D., et al. (1997) Nature 389:865-870 /	
	74 / Yang, Y., et. al. (1998) Brain Res. 804:169-176	
	75 v/Zheng, C., et al. (1993) J. Biol. Chem. 268:23933-23939 \varkappa	
	76 V Brint, et al. (1988) J. Cereb Blood Flow Metab 8:474-485 /	
	77 VAronowski, et al. (1994) Stroke 25:2235-2240	
	78 Skaper SD, Facci L, Strijbos PJ. (2000) "Neuronal protein kinase signaling cascades and excitotoxic cell death". Ann NY Acad Sci 939:11-22.	
	79 D'Orlando C, Fellay B, Schwaller B, Salicio V, Bloc A, Gotzos V, Celio M., (2001) "Calretinin and calbindin D / 28K delay the onset of cell death after excitotoxic stimulation in transfected P19 cells," Brain Research 905 1/145-158	9
M	Grant, ER, Errico, MA, Emanuel SL, Benjamin D, McMillian MK, Wadsworth SA, Zivin RA, Zhong Z, (2001 "Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells," Biochemical Pharmacology 62:283-296	

Examiner	Date	
Examine	Daic	1 , , , , , , , , , , , , , , , , , , ,
Signature	Considered	1 6-2 00
Signature	CONSIGUICA	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Application Number 09/922,874
Filing Date August 6, 2001
First Named Inventor Grant
Group Art Unit
Examiner Name
Attorney Docket Number ORT-1482

Page 1 of 1

		U.S. PATE	NT DOCUMENTS					
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)			Pages, Columns, Lines, where relevant passages or relevant figures appear		
	10.						TF.	
			R	ECFIN			Ti E	
			Mi	AV 0 0		ř		
				202	002		$\frac{2}{2}$ $\frac{2}{2}$	
	<u> </u>		TECHNOL	OGY CENT	-R D270	) [	rj	
	_				-11 11370	<del></del>	J .~	
						3/00	<i></i>	
	<del>   </del>							
	<del> </del>							
		FOREIGN PA	ATENT DOCUME	NTS		<u> </u>		

Pages, Columns, Lines, where relevant passages or relevant figures Foreign Patent Document Name of Patentee or Cite Examiner Applicant of Cited Document appear KindCode<sup>5</sup> Office<sup>3</sup> Number<sup>4</sup> Initials No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  $\mathsf{T}^2$ Cite No.<sup>1</sup> Examiner PCT Search Report for PCT/US 01/24659 dated February 22, 2002

Examiner	1///	Date	e-02 A2
		Considered	・フーレットのコ
Signature		0011010101	

5

PTO/SB/08A\_(08-00)

Approved for use through 10/31/2002. OMB 065\_UB1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMPLETED to a collection of information unless it distributed to the collection of information unless it distributed to the collection of th

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control in for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

09/922,874 Application Number -August 6, Filing Date First Named Inventor Grant Group Art Unit Examiner Name ORT-1482 Attorney Docket Number

Sheet 1 of 1 **U.S. PATENT DOCUMENTS** Pages Columns, Lines, U.S. Patent Document **Date of Publication** Name of Patentee or Applicant where relevant passages or relevant figures appear of Cited Document Kind Code Cite Examiner of Cited Document (if known) mm-dd-yyyy Initials Number No.1 08/11/1992 Hoechst Aktiengesellschaft Α US5138058 TECHNOLOGY CENTER RET EOPEIGN PATENT DOCUMENTS

Foreign Patent Document		Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	<b>-</b> -6	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup> Ki	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	figures appear	-
TAK		EP	0 384 370	Α	Hoechst	8/29/1990		
MI		EP.	0 945 443	Α	Janssen Pharmaceutica N.V.	9/29/1999		
110								
		·		<del>                                     </del>				
		<u> </u>		<del> </del>				
<b> </b>		<b> </b>		<del> </del>				
1	ļ.		İ	1		<u></u>		

Examiner	Date Considered	5-23-03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with	MPEP 609. Dra	w line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark

and not considered. Include copy of this form with next communication to applicant. 1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.